novo nordisk, eli lilly have strong first-mover advantage: analyst
Published 1 month ago • 1K plays • Length 3:45Download video MP4
Download video MP3
Similar videos
-
4:17
barclays: novo nordisk and eli lilly have first-move advantage in the obesity drug race
-
2:49
eli lilly and novo nordisk are ahead in manufacturing but need time to meet demand, says louise chen
-
6:14
new developments in weight-loss drugs: novo nordisk, eli lilly & pfizer advance studies
-
1:46
eli lilly releases new form of weight loss drug zepbound for half the price to boost access, supply
-
7:35
eli lilly's zepbound single-dose vials will expand access to more patients: mizuho's jared holz
-
5:50
eli lilly narrows gap with novo nordisk
-
4:35
jim cramer weighs the market impact of eli lilly and novo nordisk's weight loss drugs
-
3:23
market navigator: playing big pharma and eli lilly
-
3:54
former fda commissioner: expect more competition in eli lilly and novo nordisk's weight-loss drugs
-
5:47
zealand's obesity drug shouldn't disrupt novo nordisk-eli lilly leadership: mizuho's jared holz
-
5:53
eli lilly and novo nordisk will remain leaders in the weight-loss drug market: mizuho's jared holz
-
5:50
eli lilly narrows gap with novo nordisk
-
3:39
what eli lilly, novo nordisk earnings show about glp-1 sales
-
3:34
why are novo nordisk & eli lilly on the upswing? | weight-loss drugs | n18v
-
3:30
goldman sachs raises target on eli lilly: here's why
-
6:13
obesity weight loss market will remain a duopoly between novo nordisk and eli lilly: bofa’s meacham
-
2:49
jim cramer explains why he favors eli lilly in the weight loss drug space
-
3:58
eli lilly hits record high: here's what investors need to know
-
1:50
eli lilly notches best week on record: how to trade the run